Biofrontera AG /
Biofrontera AG: First Ameluz? sales in Central Eastern European region
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Leverkusen, 6 August 2014 - Biofrontera (AIM/FSE:B8F), the European
biopharmaceutical company, has started selling its prescription drug Ameluz(?)
for the treatment of actinic keratosis in Slovenia, representing the first
Ameluz(?) sales in a Central Eastern European country. Biofrontera Pharma GmbH
is the official distributor in Slovenia, working in conjunction with its local
partner PHA FARMED d.o.o., Ljubljana. The PDT treatment and Ameluz(?) are fully
reimbursed by the public health care system in Slovenia.
Four clinics have now introduced PDT with Biofrontera's PDT lamp BF-RhodoLED(?)
and had first Ameluz(?) prescriptions, already an excellent coverage for a small
country such as Slovenia. Ameluz(?) PDT is now available at the
* Derma Centre Maribor.
* University Clinical Centre in Ljubljana University Dermatovenerological
* University Medical Centre in Maribor, Department of Dermatology and
* General Hospital in Celje, Department of Dermatovenerology.
Dermatologist Dr. Sandi Luft, founder of the Derma Centre Maribor, is the first
who started using PDT with BF-RhodoLED(?) and Ameluz(?) in Slovenia:
"At first, I always prioritize patient and the treatment results. If the
efficiency of the treatment is satisfying, I am very confident to recommend the
therapy to my professional colleges and other patients. Actinic keratosis is a
common skin disease, which is recently successfully treated by PDT. Derma Centre
Maribor has just implemented PDT with BF-RhodoLED(? )and the medicine Ameluz(?).
The results show that no more than two visits of patients are needed to achieve
almost complete clearance, which is not common with other available treatments
of actinic keratosis. I can only confirm that my patients are very satisfied
also with the excellent cosmetic result."
Slavica Camer, CEO of the local representative PHA FARMED, commented: "All the
healthcare stakeholders in Slovenia have agreed on the value of PDT with
Ameluz(?). The national regulators and insurance companies have recognised the
fact that this treatment option is, due to its unmatched clearance rates, saving
money for the health care system in the long run, and have made full
reimbursement possible. Consequently, patients in Slovenia have now the
possibility to be treated with the most efficient treatment option available for
Biofrontera AG +49 (0) 214 87 63 2 0
Prof. Hermann Lübbert, Chief Executive Officer firstname.lastname@example.org
Thomas Schaffer , Chief Financial Officer www.biofrontera.com
Anke zur Mühlen, Corporate Communications
Brainwell Asset Solutions +49 (0) 152 08931514
finnCap (Nomad and Broker) +44(0) 20 7220 0500
Geoff Nash / Christopher Raggett (Corporate Finance)
Steven Norcross(Corporate Broking)
Seton Services Limited (IR) +44 (0) 20 7603 6797
Gable Communications +44 (0) 20 7193 7463
Justine James / John Bick +44 (0) 7872 061007
Notes to Editors:
Biofrontera AG (AIM/FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company
specialising in the development and distribution of dermatological drugs and
medical cosmetics for the treatment and care of skin diseases. Biofrontera's
main product is Ameluz(?), a prescription drug approved for use in Europe for
the treatment of mild to moderate Actinic Keratosis (superficial skin cancer) by
photodynamic therapy (light therapy). Biofrontera is the first small German
pharmaceutical company to receive a centralized approval for a drug developed
in-house. The Company is looking to further develop Ameluz(?) for use in Basal
Cell Carcinoma and is currently progressing through regulatory approvals to sell
the product in other territories, in particular the largest pharmaceutical
market, the USA.
In addition, the Company markets the Belixos(?) cosmetic series with plant
extracts, currently available in cream and liquid formulations which offer
nurturing and regenerating effects for people suffering from pruritus, dry skin
or chronic ailments such as eczema or psoriasis.
Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the CEO, and
is headquartered in Leverkusen, Germany.
This press release contains forward-looking statements based on the currently
held beliefs and assumptions of the management of Biofrontera AG, which are
expressed in good faith and, in their opinion, reasonable. Forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause the assumptions expressed or implied in this press release to be
faulty. Given these risks, uncertainties and other factors, recipients of this
document are cautioned not to place undue reliance on the forward-looking
statements. Biofrontera AG disclaims any obligation to update these forward-
looking statements to reflect future events or developments.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via GlobeNewswire